|
| ID |
DDInter1694 |
| Drug Type |
small molecule |
| Molecular Formula |
Na2O9Si3Zr |
| Molecular Weight |
-
|
| Description |
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent.[L2933] It is administered orally and is odorless, tasteless, and stable at room temperature.[L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.[L2933] The treatment effect was maintained for up to 12 months.[L2933]
|
| ATC Classification |
V03AE10
|
| IUPAC Name |
Disodium 1,3,5,2,4,6-Trioxatrisilinane-2,2,4,4,6,6-Hexakis(Olate) Zirconium |
| InChI |
Inchi=1S/2Na.O9Si3.Zr/C;;1-10(2)7-11(3,4)9-12(5,6)8-10;/Q2*+1;-6; |
| InChI Key |
ARVUQMBOTBOHPL-UHFFFAOYSA-N |
| Canonical SMILES |
[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1 |
| Useful Links |
DrugBank
|